Management of Anaplastic Large Cell Lymphoma.

Management of Anaplastic Large Cell Lymphoma. Hematol Oncol Clin North Am. 2017 Apr;31(2):209-222 Authors: Chihara D, Fanale MA Abstract Anaplastic large cell lymphoma (ALCL) is one of the most common peripheral T-cell lymphomas, and the incidence is higher in blacks than non-Hispanic whites. ALK-positive and ALK-negative ALCL are distinct subtypes that have different characteristics and clinical outcomes. Breast implant-associated ALCL is a rare lymphoma that has a good survival outcome, and a recent study showed that total capsulectomy is essential for treatment. Brentuximab vedotin (BV) is a standard treatment for relapsed/refractory ALCL. The response rate is high at 80-90%; however, once the disease progresses in patients on BV, survival outcome is very poor, with a median overall survival of less than two months. PMID: 28340874 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/28340874?dopt=Abstract

Source: Clinical Lymphoma and Myeloma - March 28, 2017 Category: Cancer & Oncology Authors: Chihara D, Fanale MA Tags: Hematol Oncol Clin North Am Source Type: research